GI Permeability Change in Response to Aquamin®

Healthy Clinical Trial

Official title:

Direct Measurement of Gastrointestinal Permeability Change in Response to Aquamin®

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04855799
• Other study ID #: HUM00156676 sub-study 1
• Status: Recruiting
• Phase: Phase 2
• Start date: November 2, 2021
• Est. completion date: January 2025

Study information

• Verified date: April 2024
• Source: University of Michigan
• Contact: Muhammad Nadeem Aslam
• Phone: 734-936-1897
• Email: mnaslam[@]umich.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is being completed to learn about how Aquamin® affects gastrointestinal permeability, or the control of material passing from inside the gastrointestinal tract through the gut wall into the rest of the body, in people with ulcerative colitis (UC), Irritable Bowel Syndrome with diarrhea (IBS-D), and in healthy individuals.

Description:

This is a sub-study to the ongoing clinical trial entitled: Aquamin®, a multi-mineral natural product from red marine algae, as an adjuvant intervention for mild ulcerative colitis and ulcerative colitis in remission (HUM00156676) NCT# NCT03869905.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2025
• Est. primary completion date: August 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria for UC participants:

• Must be able to give written informed consent

• Age 18 to 80 years old.

• Must have: Ulcerative colitis with confirmed diagnosis by histology and endoscopy; and be in stable remission for 3 months or more without therapy or with maintenance therapy (except steroids and antibiotics for 3 months) or have mild ulcerative colitis. Note: Corticosteroids (a type of steroid drug such as prednisone or cortisol that helps the body to regulate stress response, immune response and inflammation) and antibiotics can be used during a flare-up once the study has begun and the subject enrolled.

• A negative pregnancy test for pre-menopausal women with intact female reproductive organs. Must agree to use appropriate birth control over the study period (if applicable).

If cessation of menses is within 12 months, then the participant will be treated as pre-menopausal and a pregnancy test will be performed.

Inclusion Criteria for Healthy participants:

• Must be able to give written informed consent

• Be generally healthy, male or female, ages 18 to 80 years old.

• Pre-menopausal women with intact female reproductive organs must have a negative pregnancy test within 2 weeks of the Baseline Visit.

• Subject must agree to use appropriate birth control over the study period. (Post-menopausal is defined as no menses for the previous 12 months. If cessation of menses is within 12 months, then the participant will be treated as pre-menopausal and a pregnancy test will be performed.

Inclusion Criteria for participants with IBS-D:

• Patients with ages 18-80 years old.

• Must meet the IBS-D Diagnostic Rome IV (four) Criteria as noted in the protocol

• A negative pregnancy test for pre-menopausal cis-women with intact vagina, uterus, and/or ovaries. The negative pregnancy test must be within 2 weeks of the baseline visit and the subject must agree to use appropriate birth control over the study period.

Exclusion Criteria For UC participants:

• Must not be pregnant or lactating

• Must not be participating in any other interventional trial using an investigational drug.

• Subjects likely to be uncooperative or unable to comply with study procedures

• Participants must not be felt to have active ulcerative colitis for 3 months before study enrollment (with an exception of mild ulcerative colitis).

• Participants must not have a history or diagnosis of any of the following conditions:

Crohn's disease, Any stomach or intestinal bleeding disorders (gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors) or active gastric/duodenal ulcers - peptic ulcer disease (without bleeding in last 3 months).

• Must not have any gastrointestinal or colonic malignancy.

• Must not have Kidney disease, including kidney "stones" or hypercalcemia.

• Must not have Coagulopathy/hereditary hemorrhagic disorders

• Participants will be excluded if they have taken certain medications (per protocol), within the last 30 days or are unwilling to forgo the following for 30 days prior to entry into the study.

Exclusion Criteria For Healthy participants:

• Must not be pregnant or lactating.

• Must not be participating in any other interventional trial using an investigational drug.

• Participants must not have a history or diagnosis of any of the following conditions:

Kidney disease, including kidney "stones" or hypercalcemia, Crohn's disease, Neurologic disease, other inflammatory bowel disease, any stomach or intestinal bleeding disorders (gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors) or active gastric/duodenal ulcers - peptic ulcer disease (without bleeding in last 3 months).

• Not have Coagulopathy/hereditary hemorrhagic disorders

• Any gastrointestinal or colonic malignancy.

• Participants will be excluded if they have taken certain medications (per protocol), within the last 30 days or are unwilling to forgo the following for 30 days prior to entry into the study.

Exclusion Criteria for participants with IBS-D:

• Must not be pregnant or lactating

• Must not be participating in any other interventional trial using an investigational drug.

• Participants must not have a history or diagnosis of Crohn's disease or Inflammatory bowel disease, any stomach or intestinal bleeding disorders (gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors) or active gastric / duodenal ulcers - peptic ulcer disease (without bleeding in last 3 months).

• Must not have any gastrointestinal or colonic malignancy.

• Must not have kidney disease, including kidney "stones" or hypercalcemia, Coagulopathy/hereditary hemorrhagic disorders, neurologic disease

• Participants will be excluded if they have taken certain medications (per protocol), within the last 30 days or are unwilling to forgo the following for 30 days prior to entry into the study.

Related Conditions & MeSH terms

• Diarrhea
• Healthy
• Irritable Bowel Syndrome
• Irritable Bowel Syndrome With Diarrhea
• Ulcerative Colitis

Intervention

Drug:
• Aquamin
Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).

Locations

Country	Name	City	State
United States	University of Michigan Hospital	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
James Varani

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the lactulose:mannitol ratio in urine by comparing values at 90-days (post-intervention) to baseline (pre-intervention) levels.		Baseline (pre-intervention), 90 days (post-intervention)